At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial
In Brief
A Phase 3 clinical trial evaluating Bevacizumab, Atezolizumab, and 2 other interventions for Recurrent Ovarian Carcinoma. Completed, enrolled 574 participants across 111 sites in 12 countries.
Detailed Summary
This is a phase III, randomized, partially blinded, multicenter trial to evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy compared to placebo plus bevacizumab and chemotherapy in patients with recurrent ovarian-, fallopian tube, or primary peritoneal cancer with 1st or 2nd relapse within 6 months after platinum based chemotherapy or 3rd relapse.
Study Details
Timeline
Interventions
Bevacizumab will be administered by intravenouse route at a dose of 10mg/kg q14 during the treatment period
Atezolizumab will be administered by intravenous route at a dose of 840 mg q14 during the treatment period
Chemotherapy (Paclitaxel or PLD) will be administered by intravenous route at different doses during the treatment period q28
Placebo will be administered by intravenous route q14 during the treatment period